TEL-AVIV, Israel and PORTLAND, Oregon, October 2 /PRNewswire/ --
- Bioreactance-based Noninvasive Measurements During Exertion Identified Abnormalities of Cardiovascular Function and Might be Useful for Indexing Disease Severity, Prognostication, and for Tracking Responses to Treatment in Clinical Practice and Trials
Results from a multicenter study of Cheetah Medical's Exercise Cardiac Output (ECO(R)) stress test protocol for chronic heart failure were published earlier this month in the Journal of Cardiac Failure, the official journal of the Heart Failure Society of America and the Japanese Heart Failure Society. With approximately 6 million Americans diagnosed with heart failure, it is a leading cause of morbidity and mortality. After heart failure is diagnosed, the 1-year mortality rate is high, with 1in 5 dying. Eighty percent of men and 70% of women 65 years of age who have heart failure will die within 8 years, and one in 8 US deaths has HF mentioned on the death certificate. Unfortunately, heart failure specialists have limited tools with which to monitor heart failure progression, determine prognosis and response to treatment. Recently, it was shown that peak Cardiac Output and Peak Cardiac Power Output are the strongest predictors of heart failure severity, however access to these current methods is limited to a minute portion of heart failure patients due to cost and complexity of the devices.
In this study, Cheetah Medical's NICOM(R) System was used to continuously monitor the Cardiac Output response during exercise stress testing as well as Cardiac Power Output and a host of other hemodynamic parameters in patients with varying degrees of chronic heart failure and compared to the traditional method of measuring oxygen consumption which are obtained from analysis of expired gases. The results from both methods correlated extremely well, demonstrating the potential to use the NICOM system to routinely monitor heart failure patients without the significant limitations of expired breath gas technologies.
Matthew Maurer MD, Director of the Clinical Cardiovascular Research
Laboratory for the Elderly, Associate Professor of Clinical Medicine at
Daniel Burkhoff, M.D., Ph.D., Medical Director of Cheetah Medical, an
Adjunct Associate Professor of Medicine at
About Cheetah Medical
Cheetah Medical delivers accurate noninvasive cardiac output (CO), noninvasive blood pressure (NIBP), stroke volume variation (SVV), total peripheral resistance (TPR) and other vital hemodynamic monitoring parameters to provide continuous, clinically actionable information for fluid and drug optimization in acute and ambulatory care settings, including intensive care, emergency, perioperative care, dialysis and outpatient cardiology. The NICOM(R) Noninvasive Cardiac Output & Hemodynamic Monitoring System uses Cheetah Medical's proprietary BIOREACTANCE(R) Technology, which has validated performance accuracy and faster directional changes compared to invasive CO measurement methods, with less potential costs and risks. Cheetah Medical worldwide headquarters are located in Tel-Aviv, Israel and its United States headquarters are located in Portland, Oregon. For more information, visit our website at http://www.cheetah-medical.com.
For More Information Contact: Yoav Avidor, MD Chief Executive Officer Cheetah Medical email@example.com Telephone: +972-3-644-0288
SOURCE Cheetah Medical Ltd
|SOURCE Cheetah Medical Ltd|
Copyright©2009 PR Newswire.
All rights reserved